Challenges and considerations in multi-epitope vaccine design surrounding toll-like receptors
- 26 November 2024
- journal article
- research article
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 45 (12) , 1104-1118
Abstract
No abstract availableKeywords
This publication has 92 references indexed in Scilit:
- Molecular characterization of Anaplasma ovis Msp4 protein in strains isolated from ticks in Turkey: A multi-epitope synthetic vaccine antigen design against Anaplasma ovis using immunoinformatic toolsBiologicals, 2024
- Toll-like receptor (TLR) agonists as a driving force behind next-generation vaccine adjuvants and cancer therapeuticsCurrent Opinion in Chemical Biology, 2022
- Simplified Monopalmitoyl Toll‐like Receptor 2 Ligand Mini‐UPam for Self‐Adjuvanting Neoantigen‐Based Synthetic Cancer VaccinesChemBioChem, 2020
- Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple MyelomaJAMA Oncology, 2018
- Evolving Insights for MHC Class II Antigen Processing and Presentation in Health and DiseaseCurrent Pharmacology Reports, 2017
- Synthesis, Characterization and Immunological Evaluation of Self‐Adjuvanting Group A Streptococcal Vaccine Candidates Bearing Various Lipidic Adjuvanting MoietiesChemBioChem, 2017
- Linkers in the structural biology of protein–protein interactionsProtein Science, 2013
- HLA class I allele promiscuity revisitedImmunogenetics, 2011
- The optimization of helper T lymphocyte (HTL) function in vaccine developmentImmunologic Research, 1998
- Enhancement of peptide immunogenicity by insertion of a cathepsin B cleavage site between determinants recognized by B and T cellsResearch in Immunology, 1993